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A major limitation in the simian immunodeficiency virus (SIV) system has been the lack of reagents with which to identify
the antigenic determinants that are responsible for eliciting neutralizing antibody responses in macaques infected with
attenuated SIV. Most of our information on SIV neutralization determinants has come from studies with murine monoclonal
antibodies (MAbs) produced in response to purified or recombinant SIV envelope proteins or intact SIV-infected cells for
relatively short periods of time. While these studies provide some basic information on the potential immunogenic
determinants of SIV envelope proteins, it is unclear whether these murine MAbs identify epitopes relevant to antibody
responses elicited in monkeys during infection with either wild-type or attenuated SIV strains. To accomplish maximum
biological relevance, we developed a reliable method for the production of rhesus monoclonal antibodies. In the present
study, we report on the production and characterization of a unique panel of monoclonal antibodies derived from four
individual monkeys inoculated with SIV/17E-CL as an attenuated virus strain at a time when protective immunity from
pathogenic challenge was evident. Results from these studies identified at least nine binding domains on the surface
envelope glycoprotein; these included linear determinants in the V1, V2, cysteine loop (analogous to the V3 loop in human
immunodeficiency virus type 1), and C5 regions, as well as conformational epitopes represented by antibodies that bind the
C-terminal half of gp120 and those sensitive to defined mutations in the V4 region. More importantly, three groups of
antibodies that recognize closely related, conformational epitopes exhibited potent neutralizing activity against the vaccine
strain. Identification of the epitopes recognized by these neutralizing antibodies will provide insight into the antigenic
determinants responsible for eliciting neutralizing antibodies in vivo that can be used in the design of effective vaccine
strategies. © 2001 Academic PressINTRODUCTION
Simian immunodeficiency virus (SIV) infection of rhe-
sus macaques provides a valuable animal model for
evaluating candidate vaccine strategies for human im-
munodeficiency virus type 1 (HIV-1). Protective immune
responses have been achieved by the inoculation of
monkeys with SIV strains of low pathogenic potential
(Daniel et al., 1992; Clements et al., 1995; Wyand et al.,
1996; Lohman et al., 1994; Johnson et al., 1999; Almond et
al., 1995; Van Rompay et al., 1996, 1998; Marthas et al.,
1993). We have previously reported sterile protection
from such an attenuated macrophage-tropic strain
(Clements et al., 1995). However, protection was depen-
dent on the length of time after infection with the atten-
uated strain; monkeys infected for at least 8 months were
1 To whom correspondence and reprint requests should be ad-
ressed at Department of Pediatrics, Tulane University Medical School,
430 Tulane Avenue, New Orleans, LA 70112. Fax: (501) 584-2613.
-mail: jrobinso@tulane.edu.
59protected while those challenged earlier failed to be
protected from pathogenic SIV infection. In addition, this
protection correlated with a well-characterized matura-
tion of the antibody responses directed to the envelope
glycoproteins (Cole et al., 1997a; Fuller et al., 1997; Mon-
telaro et al., 1998).
Essential to understanding the nature of the protective
immunity elicited by infection with SIV/17E-CL is a de-
tailed investigation of the virus-specific antibody re-
sponses in monkeys infected with the attenuated SIV.
Results from such studies will not only provide informa-
tion about the specificity of antibody responses, but also
can be useful in assessing the effects of envelope vari-
ation on viral antigenic properties and immune escape.
Although a number of laboratories have developed a
variety of murine monoclonal antibodies (MAbs) to ex-
amine the immunogenic properties of SIV envelope pro-
teins, a major limitation in the SIV system has been the
lack of reagents with which to identify the antigenic
determinants that are responsible for eliciting neutraliz-
ing antibody responses in macaques infected with atten-
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60 COLE ET AL.uated SIV. Early studies by our laboratory (Miller et al.,
1992) and others (Torres et al., 1993a) described the
reactivity of immune sera from SIV-infected macaques
with extensive panels of synthetic peptides. Identifica-
tion of these linear determinants was subsequently over-
shadowed by the observation that the principal neutral-
izing determinant of SIV gp120 could not be represented
as a simple linear peptide and that the reactivity of
neutralizing antibodies was dependent on the conforma-
tion of the V3 and V4 domains of gp120 (Javaherian et al.,
1992, 1994).
Most of our information on SIV neutralization determi-
nants has come from studies with murine MAbs pro-
duced in response to purified or recombinant SIV enve-
lope proteins and more recently intact SIV-infected cells
(Edinger et al., 2000). Linear neutralizing determinants
including epitopes in V1 (Jurkiewicz et al., 1997), V2
(Babas et al., 1994, 1997; Benichou et al., 1992; Kent et al.,
1991, 1992), V3 (Babas et al., 1994, 1995; Palker et al.,
1996), V4 (Babas et al., 1994; Javaherian et al., 1994; Kent
et al., 1991), and the ectodomain of gp41 (Babas et al.,
1997; Kent et al., 1991, 1992; Kodama et al., 1991) have
been reported. Importantly, several murine MAbs have
been shown to recognize conformation-dependent
epitopes. The binding of these neutralizing antibodies
that display a conformational dependence is influenced
by sequence changes in the V3 and V4 domains of SIV
gp120 and these antibodies have also been shown to
bind a protease fragment of gp120 that contains the V3
through V5 domains (Javaherian et al., 1992, 1994). More
recently, Edinger et al. (2000) described the production of
conformation-dependent, neutralizing MAbs that recog-
nize the CD4 or CCR5 binding sites on SIV gp120 follow-
ing immunization of mice with intact infected cells. While
these studies provide some basic information on the
potential immunogenic determinants of SIV envelope
proteins, it is unclear whether these murine MAbs iden-
tify epitopes relevant to antibody responses elicited in
monkeys during infection with either virulent or attenu-
ated SIV strains. To accomplish maximum biological rel-
evance, we developed a reliable method for the produc-
tion of rhesus MAbs (Robinson et al., 1998). In the
present study, we report the production and character-
ization of a unique panel of rhesus MAbs derived from
four individual monkeys inoculated with SIV/17E-CL as
an attenuated virus strain (Clements et al., 1995). Impor-
tantly, these antibodies were derived from monkeys that
had developed protective immune responses elicited by
a live virus.
RESULTS
Production of rhesus monoclonal antibodies
recognizing SIV gp120We previously reported the production and character-
ization of 5 rhesus MAbs derived from a single monkey(L471) infected with an attenuated macrophage-tropic
virus, SIV/17E-CL (Robinson et al., 1998). We have now
produced 18 additional rhesus MAbs from three other
similarly infected monkeys (L235, L652, and M118)
(Clements et al., 1995; Cole et al., 1997b) and report here
the characteristics of the cumulative panel of MAbs. For
the purposes of comparative analysis, we included in
these studies 4 human MAbs generated from an HIV-2-
infected patient (Robinson et al., 1998). As summarized in
Table 1 each of the rhesus MAbs recognized the major
surface viral envelope glycoprotein, gp120, as deter-
mined by ELISA and Western blot assays. Six rhesus
MAbs reacted strongly with reduced gp120 in Western
blot assays, suggesting that they recognized linear
epitopes; the remaining MAbs either showed no reactiv-
ity with reduced gp120 or were very weakly reactive, as
previously reported (Robinson et al., 1998), providing
evidence that their binding sites were conformationally
dependent. In peptide ELISAs the same six MAbs that
were reactive with reduced gp120 were also reactive
with five synthetic peptides representing linear epitopes
in V1, V2, cysteine loop/V3, and the C-terminus of SIV
gp120, respectively (Table 1). These rhesus MAbs re-
acted as follows: 3.10A to amino acids 141–160 (V1), 5.5B
to amino acids 161–180 (V2), 3.11H and 3.11G to amino
acids 311–330 (cysteine loop/V3), C31 to amino acids
321–340 (also in the cysteine loop/V3), and 5.3G to amino
acids 501–520 in the carboxy-terminus of gp120. The
other rhesus MAbs failed to react with any of the syn-
thetic peptides, indicating a predominant specificity for
conformationally dependent epitopes.
Cross-reactivity of rhesus MAbs with SIV and
HIV-2 strains
Rhesus MAbs were tested for cross-reactivity with a
panel of SIV and HIV-2 strains. As summarized in Table 2,
the majority of the rhesus MAbs were cross-reactive with
gp120s from SIV/17E-CL, SIVmac239, and SIVmac251. In
addition, some rhesus MAbs were also reactive with
gp120s from the more divergent strain SIVsmH3 and its
replication-defective derivative SIVsmB7. These included
peptide-reactive MAbs 5.5B, 3.11G, 3.11H, and 5.3G as
well as two MAbs (3.11E and 3.2C) that recognized con-
formational epitopes on gp120. Amino acid alignments of
the SIV strains tested (Fig. 1) revealed that the linear
epitopes recognized by these broadly reactive antibod-
ies fell within highly conserved regions of gp120. In
contrast, two peptide-reactive MAbs, 5.5B and C31, did
not bind mac239 gp120, which is in accord with the
observation that their respective linear epitopes are
within divergent regions in mac239-related strains (Fig.
1). Nevertheless, 5.5B was one of five rhesus MAbs that
recognized gp120 from the more divergent SIVsmH3/
smB7. None of the rhesus MAbs was cross-reactive with
any of the three HIV-2 strains tested. These findings
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61NEUTRALIZATION EPITOPES OF SIVcontrast with the broad cross-reactive binding activity
observed with all four human MAbs derived from an
HIV-2-infected patient (Robinson et al., 1998).
Cross-competition analyses of rhesus MAbs
identified nine binding domains on SIV gp120
To determine the topological relationships between
epitopes recognized by the rhesus and human MAbs, we
tested the ability of each MAb to block binding of biotin-
labeled MAbs to SIV/17E-CL gp120. In our earlier study
characterizing 5 rhesus MAbs, we identified three com-
petition groups (Robinson et al., 1998). In the present
study, we have expanded this characterization to include
a total of 22 rhesus MAbs. As summarized in Fig. 2,
results from the cross-competition assays revealed that
T
Characteristics of R
MAbs
Con A ELISA
17E-CL rgp140
Western blot
mac251 rgp110
React
45-kDaNonreduced Reduced
Rhesus MAbs
H31 (M118) 1 1 2
3.8E (M118) 1 1 2
3.10A (M118) 1 1 11
5.5B (L235) 1 1 11
3.11G (M118) 1 1 11
3.11H (M118) 1 1 11
C31 (M118) 1 1 11
1.1C (L471) 1 1 1Þ2
1.11A (L471) 1 1 1Þ2
4.7A (M118) 1 1 1Þ2
2.10F (L652) 1 1 1Þ2
3.11E (M118) 1 1 2
3.2C (M118) 1 1 1Þ2
1.5A (L235) 1 1 2
E31 (L235) 1 1 2
1.6A (M118) 1 1 2
1.7F (L471) 1 1 2
1.10A (L471) 1 1 2
3H3 (M118) 1 1 2
C26 (M118) 1 1 2
3B3 (M118) 1 1 2
5.3G (L235) 1 1 11
Human MAbs
2.6C 1 1 2
1.10C 1 1 2
B23 1 1 2
1.7A 1 1 2
Note. Neutralization index (NI) 5 log10TCID50 without MAb—log10TCthe rhesus MAbs could be placed into nine competition
groups recognizing nine corresponding binding regionson SIV gp120. Rhesus MAbs within a given group com-
peted reciprocally with one another for binding to solid-
phase gp120. In addition, antibodies in Groups I, II, III, IV,
VIII, and IX were able to block binding of antibodies only
within their specific binding group, indicating that each
of these groups recognized distinct sites. In contrast, the
competition patterns among rhesus MAbs in Groups V,
VI, and VII were more complex. For example, Group V
(1.1C, 1.11A, and 4.7A) MAbs not only competed with one
another but also were able to compete moderately well
with Group VI antibodies. However, Group V MAbs were
unable to block binding of Group VII MAbs (1.7F, 1.10A,
C26, and 3H3). Group VI (2.10F, 3.2C, 3.11E, 1.5A, E31, and
1.6A) antibodies were able to inhibit gp120 binding of
both Group V and VII MAbs. Group VII MAbs were able
and Human MAbs
th
nt
Peptide
reactivity
Sensitivity to
V4 mutations
17E-CL
neutralization
(log10 NI)
Competition
group
2 2 0.41 I
2 2 ,0.25 I
aa 141–160 (V1) 2 0.41 II
aa 161–180 (V2) 2 0.58 III
aa 311–330
(Cys Loop/V3)
2 0.75 IV
aa 311–330
(Cys Loop/V3)
2 ,0.25 IV
aa 321–340
(Cys Loop/V3)
2 1.0 IV
2 2 1.66 V
2 2 2.8 V
2 2 2.0 V
2 2 3.0 VIa
2 2 2.0 VIa
2 1 2.33 VIb
2 1 2.0 VIb
2 1 2.16 VIb
2 1 1.9 VIb
2 1 2.0 VII
2 1 2.0 VII
2 1 2.8 VII
2 1 3.0 VII
2 2 0.25 VIII
aa 501–520
(C-terminus)
2 nt IX
2 2 0.41 I
2 2 2.58 VIa
2 2 2.75 VIa
2 1 2.75 VIc
th MAb; results are the mean of three experiments.ABLE 1
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fragme
2
2
2
2
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
nt
2
1
1
1to block binding of some Group VI MAbs (with 2.10F and
3.2C being exceptions), but not any Group V MAbs. The
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62 COLE ET AL.competition patterns of three human MAbs (110C, 1.7A,
and B23) were the same as those of Group VI. These
results suggest that the binding sites of Groups V and VII
MAbs are distinct from each other, but that the binding
sites of Group VI MAbs significantly overlap the sites
recognized by both Groups V and VII and in fact may be
positioned between Group V and VII epitopes.
Neutralizing activity of rhesus MAbs is confined to
three competition groups
We assessed the ability of the rhesus and human
MAbs to neutralize SIV/17E-CL using end-point dilution
virus titrations to determine the difference in the log10
TCID50 titers between virus incubated with MAbs or with
FIG. 1. Envelope gp120 amino acid alignment of SIV and HIV-2 strai
ere aligned using MacVector. The sequence for SIV/17E-CL has been
sequence. Sequences for gp120s from SIVmac239, SIVmac251, SIVm
T
Cross-Reactivity of MAbs with gp120s
MAbs 17E-Cl mac251 mac239
Rhesus
3.8E 1 1 1
H31 1 1 1
3.10A 1 1 1
5.5B 1 1 2
3.11G 1 1 1
3.11H 1 1 1
C31 1 1 2
1.1C 1 1 1
1.11A 1 1 1
4.7A 1 1 1
2.10F 1 1 1
3.11E 1 1 1
3.2C 1 1 1
E31 1 1 1
1.6A 1 1 1
1.5A 1 1 1
1.7F 1 1 1
1.10A 1 1 1
3H3 1 1 1
C26 1 1 1
3B3 1 1 1
5.3G 1 1 1
Human
2.6C 1 1 1
1.7A 1 1 1
1.10C 1 1 1
B23 1 1 1
a The antigenic properties of SIV smH3 and SIV smB7 are identical.
b HIV-2 strains tested include D194, MS, and MVP.SIVmac142, SIVsmH3 and HIV-2/D194 were obtained from GenBank. Sequenc
for these studies, and the consensus sequence of six individual clones is reedium alone. For these experiments, we used a neu-
ralization assay that measured the ability of a constant
mount of each MAb (10 mg/ml) to reduce the TCID50 of
serial 10-fold dilutions of the homologous, inoculating
SIV/17E-CL virus strain. Results summarized in Table 1
demonstrate that all neutralizing activity (log10 neutraliza-
tion index (NI) values greater than 1.5) was clustered
predominantly within rhesus MAb Groups V, VI, and VII.
In addition, all rhesus MAbs within a given competition
group exhibited a similar magnitude of neutralization, as
determined by a close range of log10 NI values. These
data suggest that the predominant neutralizing epitopes
cluster within complex, conformational determinants of
SIV gp120 and support the conclusion that these neutral-
izing rhesus MAbs are likely to bind a group of similar or
closely related epitopes.
no acid sequences of gp120 from the indicated SIV and HIV-2 strains
usly reported (Anderson et al., 1993) and was used as the consensus
2H (the sequence used to generate the overlapping peptide panel),
IV, SIV V4 Variants, and HIV-2 Strains
r1-12 V4 mutants smH3 sm/B7a HIV-2b
1 1 2 2
1 1 2 2
1 1 2 2
2 2 1 2
1 1 1 2
1 1 1 2
2 2 2 2
1 1 2 2
1 1 2 2
1 1 2 2
1 1 2 2
1 1 1 2
2 2 1 2
2 2 2 2
2 2 2 2
2 2 2 2
2 2 2 2
2 2 2 2
2 2 2 2
2 2 2 2
1 1 2 2
1 1 2 2
1 1 1 1
2 2 1 1
1 1 1 1
1 1 1 1ns: Ami
previo
ac251.3ABLE 2
from S
vaes for SIVsmB7 gp120 (a defective clone of SIVsmH3) were generated
ported (Cole, unpublished data).
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64 COLE ET AL.Inability of rhesus MAbs to block gp120–receptor
binding
An important group of human MAbs to HIV-1 gp120 is
able to neutralize HIV-1 by blocking gp120 binding to the
cellular receptor CD4. We therefore tested whether any
of the rhesus MAbs or human MAbs in the present panel
recognized the CD4 binding site of SIV gp120 by assay-
ing the ability of candidate MAbs to block binding of
rsCD4 to solid-phase gp120. The results of these assays
demonstrate that none of the rhesus MAbs were able to
inhibit rsCD4–gp120 binding, and conversely, rsCD4 did
not inhibit binding of any rhesus MAb to SIV gp120 (data
not shown). In addition, we observed no enhanced bind-
ing of any of the rhesus MAbs to gp120–CD4 complexes,
a phenomenon that has been reported previously with
several human MAbs that recognize epitopes that man-
ifest enhanced exposure on gp120 following CD4 bind-
FIG. 2. Cross-competition analysis of rhesus MAbs. The ability of u
MAbs (listed across x-axis) to SIV/17E-CL envelope glycoproteins was d
11 indicates strong competition, 1 indicates intermediate compe
assignment of rhesus MAbs to groups in which cross-competition is cing (Thali et al., 1993). With respect to the panel of MAbs
included in these studies, the results demonstrate a
m
smarked independence of CD4 binding and rhesus MAb
binding sites on the SIV envelope protein.
Reactivity of MAbs to 45-kDa V8 protease digestion
fragment of rgp110
A 45-kDa fragment derived by V8 protease digestion of
purified rgp110 (mac251) has previously been shown to
contain the principal neutralization determinants of SIV
gp120 (Javaherian et al., 1994). We prepared similar V8
rotease digests of purified rgp110 that were fraction-
ted by sodium dodecyl sulfate–polyacrylamide gel elec-
rophoresis (SDS-PAGE) and Western blotted onto nitro-
ellulose membranes. Rhesus and human MAbs were
ested for binding to blots containing either undigested
gp110 or V8 protease-treated gp110. The results are
ummarized in Table 1 and representative examples are
hown in Fig. 3. In agreement with previous epitope-
d MAbs (listed down y-axis) to compete for binding of biotin-labeled
ed in the Con A ELISA. Entries indicate the level of competition, where
nd 0 indicates no significant competition. Shaded areas indicate
te and reciprocal.nlabele
eterminapping studies using synthetic peptides, it was ob-
erved that the 3 linear V3-reactive rhesus MAbs (3.11G,
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65NEUTRALIZATION EPITOPES OF SIV3.11H, and C31) also bound the C-terminal 45-kDa frag-
ment. Five other conformational rhesus MAbs in compe-
tition Groups V (1.1C, 1.11A, and 4.7A) and VI (2.10F and
3.11E) also reacted with the 45-kDa fragment as did 3 of
the 4 human MAbs (1.10C, B23, and 1.7A) tested. These
results suggest that 8 of the 22 rhesus MAbs bind
epitopes located in the C-terminal 45-kDa fragment of
SIV gp120 while the remaining 14 rhesus MAbs bind the
N-terminal half of gp120. One interesting observation is
that only 2 of the 6 rhesus MAbs in competition Group VI
bind the C-terminal 45-kDa fragment despite the ability of
these 6 antibodies to completely and reciprocally inhibit
binding to gp120. These results suggest that antibodies
in Group VI are likely to bind closely related but distinct
epitopes on gp120 that may involve binding sites that
overlap between the N-terminal and the C-terminal 45-
kDa fragments of SIV gp120.
Effects of alterations in V4 amino acid sequences on
rhesus MAb binding
Mutations within the V4 region of SIVmac239 have
been shown to be responsible for the failure of a group
of neutralizing murine MAbs to bind to gp120s from two
molecularly cloned SIVmac239 variants (SIV/var1-12 or
SIV/var8-22) that emerged as neutralization-resistant
variants in a rhesus monkey during infection with
SIVmac239 (Choi et al., 1994) (see Table 2). Choi et al.
1994) demonstrated that the critical mutations involved
ither the deletion of KEQH at amino acid residues 422–
25 in var1-12 or the deletion of KPKE at amino acids
20–423 in var8-22. We previously demonstrated that two
FIG. 3. Binding of MAbs to the C-terminal 45-kDa fragment of SIV-
mac251 rgp110. Rhesus MAbs C26, 3.10A, 4.7A, and 3.11E and human
MAb 1.7A were assayed for reactivity to (lanes a) undigested or (lanes
b) V8 protease digested SIVmac251 rgp110 by Western blot analyses.roup VII rhesus MAbs (1.7F and 1.10A) as well as one
uman MAb (1.7A) were unable to bind gp120 from mu-tant viruses containing either of these deletions (Robin-
son et al., 1998). We therefore tested the expanded MAb
anel for reactivity with the parent variant viruses, SIV/
ar1-12 and SIV/var8-22, and the two V4 mutant gp120s
erived from these viruses. As summarized in Table 1,
his expanded analysis demonstrated that all the Group
II MAbs (1.7F, 1.10A, C26, and 3H3) were unable to bind
p120s from either variant or from mutant viruses con-
aining the site-specific deletions D420-423 KPKE and
422-425 KEQH in the V4 region. In addition, four of six
roup VI rhesus MAbs (3.11E, E31, 1.6A, and 1.5A) and
ne Group VI human MAb (1.7A) also failed to recognize
hese same mutant gp120s. With the exception of rhesus
Abs 5.5B and C31, which do not recognize the
IVmac239 parent virus, all other rhesus MAbs in the
anel were reactive with the variant and mutant viruses.
hese results suggested that the rhesus MAbs affected
y V4 sequence alterations may recognize epitopes near
r within the V4 region of gp120. Alternatively, changes in
he V4 region could affect binding of these MAbs by
ltering the exposure of epitopes that lie outside of V4. It
s likely that mapping the conformational binding sites for
he V4-sensitive rhesus MAbs will provide important in-
ormation about the effects of sequence variation on the
ntigenic architecture of the SIV envelope.
DISCUSSION
We recently demonstrated that it is feasible to derive
hesus macaque B-cell lines secreting MAbs specific for
IV gp120 and we have shown that these rhesus MAbs
ould neutralize SIV (Robinson et al., 1998). In this report
we have extended our earlier findings and have gener-
ated an extensive panel of SIV gp120-specific rhesus
MAbs using rhesus Epstein–Barr virus-like virus (RhEBV)
transformation of peripheral blood B cells obtained from
a total of four rhesus monkeys that had been infected
with the attenuated, macrophage-tropic strain, SIV/
17E-CL (Clements et al., 1995). All four monkeys devel-
oped neutralizing antibodies to SIV/17E-CL and the het-
erologous strain SIVDeltaB670. Three of the monkeys were
later challenged by inoculation with the uncloned heter-
ologous isolate SIVDeltaB670 and were protected against
the challenge (Clements et al., 1995). The antibody panel
ncluded in this study consisted of 22 rhesus MAbs and
human MAbs derived from an HIV-2-infected patient
rom the Ivory Coast (Robinson et al., 1990b). All the
MAbs reacted with gp120 of SIV/17E-CL by ELISA and
Western blot assays. Six rhesus MAbs were able to bind
reduced gp120, and the binding sites of these rhesus
MAbs were mapped to linear epitopes in the V1, V2, the
cysteine loop (analogous to the V3 loop of HIV-1), and
C-terminal regions of gp120 as determined by their re-
activity to synthetic peptides (Table 1). By contrast, 16
rhesus MAbs and all the human MAbs recognized SIV
gp120 in a conformationally dependent manner; i.e., they
o
h
b
r
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66 COLE ET AL.failed to react with reduced gp120 in Western blots and
their binding sites could not be represented by synthetic
peptides in ELISA. Based on analyses of cross-compe-
tition, CD4 blocking, and binding to mutant gp120s de-
scribed below, a schematic representation of the de-
duced antibody binding domains is shown in a two-
dimensional representation of SIV gp120 (Fig. 4).
The cross-competition patterns of the rhesus and hu-
man MAbs indicated that they identified at least nine
binding domains on gp120 (Fig. 2). The order of place-
ment of the competition groups is based on the amino
FIG. 4. Schematic representation of rhesus antibody binding to SIV g
f rhesus MAbs are shown superimposed on a two-dimensional mo
ypothetical assignment of intrachain disulfide bonds for SIV (Hoxie, 199
model for SIV envelope glycoproteins (Gallaher et al., 1995). All rhesus
y ELISA and the linear epitopes (listed in rectangles) recognized by six
ecognize conformational epitopes (listed in ovals) are placed in the re
-term, carboxy-terminus.acid sequence of gp120 from the amino-terminus to the
carboxy-terminus (Fig. 2, left to right and top to bottom).Group I MAbs are placed at the amino-terminus because
the human MAb 2.6C has been shown to immunopre-
cipitate a protease fragment containing approximately
100 amino acids of the amino-terminal sequence of
gp120 (Cole and Montelaro, unpublished observations).
Because rhesus MAbs 3.8E and H31 reciprocally cross-
competed with 2.6C, they were also assigned to the
amino-terminus, although we cannot be certain of their
binding sites. Group II (3.10A), Group III (5.5B), and Group
IV (3.11H, 3.11G, and C31) clearly mapped to linear
epitopes of the V1, V2, and C3 regions, respectively.
he proposed locations of the epitope clusters defined by nine groups
SIV/17E-CL gp120. Drawing of the disulfide bonds is based on the
known disulfide bonds for HIV-1 (Leonard et al., 1990) and the structural
were screened for reactivity to synthetic, overlapping 20mer peptides
are shaded. The putative binding domains of the remaining MAbs that
of gp120 thought to involve antibody binding. N-term, amino-terminus;p120. T
del of
1), the
MAbs
MAbs
gionsRhesus MAb 5.3G in Group IX maps to a linear peptide in
the carboxy-terminus of gp120. We have no definitive
GG
G
G
G
67NEUTRALIZATION EPITOPES OF SIVrationale for the placement of Group VIII (3B3), which
recognizes a conformation-dependent epitope and does
not compete with any other MAb in this panel.
The locations of the binding sites recognized by the
rhesus and human MAbs in Groups V, VI, and VII are not
yet certain. The competition patterns observed between
Groups V and VII MAbs indicate that they recognize
distinct epitope clusters. However, since Group VI MAbs
were able to partially or completely inhibit binding of
MAbs in both Groups V and VII, it is possible that the
sites recognized by Group VI MAbs are located in close
proximity to, and perhaps lie between, the Group V and
the Group VII MAb binding sites. As summarized in Table
3, antibodies in Groups V, VI, and VI could be distin-
guished based on their ability to recognize the 45-kDa
protease digestion product of SIV gp110 described by
Javaherian et al. (1994) or the failure to bind gp120
containing specific amino acid alterations in V4. Rhesus
MAbs in Group V and Subgroup VIa were reactive with
the 45-kDa fragment (Fig. 3) and were not sensitive to
mutations in V4. Conversely, Group VII MAbs and Sub-
group VIb MAbs were unable to bind to gp120s contain-
ing mutant V4 sequences (deletions 420–423 KPKE and
422–425 KEQH), as described by Choi et al. (1994) and
previously demonstrated for several MAbs in this panel
(Robinson et al., 1998), but failed to bind the 45-kDa
protease digestion fragment. Although binding to the
45-kDa fragment and sensitivity to V4 mutations ap-
peared to be a mutually exclusive property for most of
these rhesus MAbs, the human MAb 1.7A (Subgroup VIa)
was a notable exception in its recognition of the 45-kDa
fragment and inability to bind gp120 containing altered
V4 sequences.
While binding to the 45-kDa protease fragment and
sensitivity to V4 mutations allow speculation of the
epitopes recognized by the antibodies in Groups V, VI,
and VII, these studies do not conclusively identify the
conformational epitopes recognized by these MAb
groups. The ability of MAbs to bind the 45-kDa fragment
clearly localizes epitopes to the C-terminal half of gp120.
However, sensitivity to V4 mutations is more difficult to
T
Binding Specificities am
MAbs
Reactive w
45-kDa fragm
roup V 1.1C, 1.11A, 4.7A 1
roup VIa
Rhesus MAbs 2.10F, 3.11E
Human MAbs 1.10C, B23 1
roup VIb 3.2C, 1.5A, E31, 1.6A 2
roup VIc Human MAb 1.7A 1
roup VII 1.7F, 1.10A, C26, 3H3 2interpret. It is uncertain whether the V4-dependent anti-
bodies recognize the actual site of the mutations or
S
twhether the mutations are located distant in sequence
from the antibody binding site and abrogate antibody
binding by altering envelope protein conformation. At-
tempts to map conformational epitopes on the HIV-1
envelope protein using site-directed mutagenesis have
indicated the influence of specific sequence variations
on antibody binding, yet they have not provided definitive
mapping of the conformational antibody binding site on
the envelope protein (Thali et al., 1991, 1992). This is
largely due to inherent limitations of this site-directed
mutagenesis strategy, in that it does not necessarily
discriminate between mutated residues located within
the actual antibody binding site from those that affect
antibody binding by altering protein conformation. Simi-
larly, our results provide indirect evidence that the differ-
ent V4-dependent MAbs recognize more than one
epitope, making it unlikely that the sites of the V4 muta-
tions are located within the actual binding sites for these
MAbs. For example, unlike the rhesus MAbs, which are
not cross-reactive with HIV-2 gp120s, human MAb 1.7A is
broadly reactive with both SIV and HIV-2 gp120s. More-
over, 1.7A is the only MAb in the panel that could bind the
45-kDa fragment and that was V4-dependent. Therefore,
the 1.7A binding site must be different from those of the
other V4-dependent rhesus MAbs. In addition, binding of
several Group VI MAbs, which exhibited competition
patterns that differed from those of Group VII MAbs, was
also affected by the same V4 mutations, suggesting that
they too identify different epitopes. Further biochemical
studies to identify the conformational epitopes recog-
nized by these three rhesus MAb groups are necessary
to define the effects of sequence variation in V4 on the
overall protein conformation of the SIV gp120 molecule.
Taken together, these results demonstrate the inability of
cross-competition analyses to yield patterns of antibody
reactivity that resolve subtle differences between or
among antibody binding groups.
The antigenic determinants responsible for eliciting
neutralizing antibody responses in macaques during
chronic SIV infection have not been completely charac-
terized. In previous studies by Javaherian et al. (1994),
oup V, VI, and VII MAbs
Sensitivity to
V4 mutations Competition pattern
2 Inhibits Group VI but not Group VII MAbs
2 Inhibits both Group V and VII MAbs
1 Inhibits both Group V and VII MAbs
1 Inhibits both Group V and VII MAbs
1 Does not inhibit Group V MAbsABLE 3
ong Gr
ith
entIV-infected monkeys produced neutralizing antibodies
hat were reactive with a 45-kDa fragment of SIV gp120
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68 COLE ET AL.that includes the V3 and V4 regions. However, the V3
region of SIV gp120 does not appear to be as important
in SIV neutralization as it is in HIV-1 (Javaherian et al.,
992), and it is unclear how many neutralization epitopes
re contained in the 45-kDa fragment compared to those
hat may lie in regions outside this fragment. In another
tudy by Torres et al. (1993b), it was found that a peptide
epresenting the V4 region of SIV gp120 could absorb
eutralizing antibodies from sera of SIV-infected mon-
eys, suggesting that a linear epitope within V4 could be
n important target of neutralizing antibodies. In the
resent study, in vitro virus neutralization data demon-
strated that all the neutralizing activity in this rhesus MAb
panel resided in Groups V, VI, and VII. Thus, it is apparent
that the targets of virus neutralization are quite hetero-
geneous. In addition, while the 45-kDa fragment has
been reported to contain the principal neutralizing do-
main of SIV gp120, this fragment may not fully represent
sites involved in antibody-mediated neutralization, as
rhesus MAbs in Groups VIb and VII have good neutral-
izing activity but do not bind the 45-kDa fragment.
Interestingly, none of the rhesus MAbs described in
this study was able to inhibit SIV gp120–rsCD4 interac-
tions. Conversely, competition experiments in which
rsCD4 was preincubated with SIV gp120 demonstrated
no effect (blocking or enhancing) on binding by any of the
rhesus MAbs. These results were not expected, since
several murine MAbs that have been generated from
mice immunized with recombinant envelope antigens
have been shown to block the gp120–CD4 interaction
(Kent and Bjorling, 1996; Gardner et al., 1995; Babas et
al., 1995) although such MAbs are not all potent in
eutralization. The failure of any of these neutralizing
hesus MAbs to block the gp120–CD4 interaction raises
everal questions regarding the mechanism of virus neu-
ralization by these MAbs. One potential mechanism of
eutralization by these rhesus MAbs may be through the
nterference of gp120–coreceptor interactions. Further-
ore, studies demonstrating that several SIV strains can
fficiently infect cells in a CD4-independent manner
Edinger et al., 1997, 1999) support the findings that these
rhesus MAbs can neutralize SIV in the absence of block-
ing the gp120–CD4 interaction and may suggest that the
CD4 binding region of SIV gp120 is poorly immunogenic
in infected monkeys. This is supported by the recent
findings by Edinger et al. (2000) that immunization of
ice with soluble or cell-associated oligomeric SIV en-
elope proteins produced antibodies capable of inhibit-
ng gp120 binding to CD4 and/or CCR5. However, all
eutralizing antibodies produced blocked infection
hrough CCR5 or the alternate coreceptor STRL33
Edinger et al., 2000). Our results are also in contrast to
he report by Glamann et al. (1998) demonstrating that it
s possible to produce SIV envelope-specific Fab frag-ents from a phage display library constructed from
NA extracted from lymph node cells of an SIV-infected enimal. They subsequently described an IgG MAb de-
ived from Fab-201 and now called IgG1-201 that neutral-
zes SIV (homologous isolate only). While they show data
hat they interpret as indicating CD4-enhanced binding
o SIV gp120, CD4-induced enhancement was observed
nly with CD4 concentrations greater than 5 mg/ml.
These rsCD4 concentrations are significantly higher than
those needed to enhance binding of human MAbs 17B
and 48D, the prototype MAbs for CD4-induced epitopes.
For example, rsCD4 induces markedly enhanced binding
of 17B and 48D to HIV-1 gp120s at concentrations as low
as 0.5 mg/ml (Robinson, unpublished observations). Fur-
ther delineation of the epitopes recognized by these
conformational, neutralizing rhesus MAbs will undoubt-
edly provide insight into the complex envelope determi-
nants involved in mediating virus neutralization.
While this panel of rhesus MAbs is likely to represent
an extremely small fraction of the SIV-specific B-cell
responses elicited by attenuated SIV infection, they pro-
vide invaluable tools for defining SIV gp120 neutralization
determinants and evaluating the effects of sequence
variation on neutralizing antibody specificity. In addition,
these studies demonstrate the need for higher resolution
mapping of the conformational epitopes recognized by
these antibodies, such as the recent identification of a
discontinuous epitope in the C5 region of HIV-1 gp120
using proteolytic protection methodology (Hochleitner et
al., 2000). These studies will aid in characterization of
immunogenic SIV envelope determinants that will pro-
vide important information for the design of effective
vaccine strategies that elicit broadly protective immune
responses.
MATERIALS AND METHODS
Cell lines, viruses, and viral envelope proteins
The cell lines CEMx174 and MT4 were maintained in
RPMI 1640 medium containing 10% fetal bovine serum.
D3-R5, a generous gift from David Dorsky (University of
Connecticut Health Center, Farmington, CT), is a cell line
derived from the human T-cell line PM1, which was
engineered to constitutively express CCR5 and to ex-
press EGFP under the control of HIV-1 LTR; except for the
ability to express EGFP instead of GFP, it is very similar
to the previously described D5-R5 cell lines in its broad
susceptibility to primary isolates of HIV-1 (Dorsky and
Harrington, 1999). We have found this cell line to be more
sensitive to infection with SIV isolates than either MT4 or
CEMx174. Consequently we used this cell line to assay
infectivity of SIV/17E-CL.
Several molecularly cloned strains were used in these
studies: SIV/17E-CL is an attenuated macrophage-tropic
clone of SIVmac239 (Anderson et al., 1993; Kinsey et al.,
1996); SIVmac239 (Daniel et al., 1985; Naidu et al., 1988;
Kestler et al., 1990), SIVmac251 (Daniel et al., 1985; Naidu
t al., 1988) and two natural variants of SIVmac239,
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69NEUTRALIZATION EPITOPES OF SIVSIV/variant1-12 and SIV/variant8-22, have been previ-
ously described (Choi et al., 1994). Two mutant
SIVmac239 viruses containing specific V4 sequence al-
terations representing the deletions found in the V4 re-
gions of SIV variant 1-12 and variant 8-22 were as de-
scribed (Choi et al., 1994). The above viruses as well as
he uncloned SIV/DeltaB670 (Baskin et al., 1986; Mur-
hey-Corb et al., 1986) and SIVsmH3 (Johnson et al.,
990) were propagated in CEMx174, MT4, or D3-R5 cells.
he following HIV-2 strains were obtained through the
IDS Research and Reference Reagent Program, Divi-
ion of AIDS, NIAID, NIH: HIV-2/D194 (Kuhnel et al., 1989)
was donated by Hagen von Brieson, HIV-2/MS was do-
nated by Phyllis Kanki, and HIV-2/MVP-15132 (Gao et al.,
993) was donated by Lutz Gu¨rtler and Friedrich Dein-
ardt. All HIV-2 strains were grown in MT4 cells. Viral
ntigen stocks containing solubilized SIV or HIV-2 enve-
ope glycoproteins were derived from supernatant fluids
ollected at 4- to 7-day intervals from cell lines chroni-
ally infected with each virus. Virus was inactivated and
olubilized by the addition of Triton X-100 at a final
oncentration of 1% to the cell culture fluids. Viral antigen
tocks were stored in aliquots at 220°C. A cell line (B7)
erived from CEMx174 cells chronically infected with
IVsmH3 releases a defective virus designated SIVsmB7
Kraiselburd and Torres, 1995). This cell line, a generous
ift from Edmundo Kraiselburd, expresses large amounts
f envelope glycoprotein that is antigenically indisguish-
ble from that from the parent SIVsmH3. Hence, the
nvelope glycoproteins of both viruses can be referred to
s SIVsmH3/B7 (Table 2).
The following recombinant SIV envelope antigens
ere used in these studies: SIVmac251 rgp110 (rgp110)
as expressed in baculovirus, propagated in insect
ells, and purified by immunoaffinity chromatography as
reviously described (Javaherian et al., 1992); SIV/17E-CL
p140 (rgp140) was also expressed in the baculovirus
ystem and propagated in insect cell cultures using
erum-free medium, and supernatant fluids containing
he recombinant envelope protein were concentrated
0-fold using a Quikstand Benchtop concentrator (A/G
echnologies). Recombinant protein stocks were stored
t 220°C.
hesus EBV transformation of rhesus monkey B cells
A RhEBV produced by the H254 cell line (Rangan et al.,
986) was used to transform rhesus B cells into contin-
ous cell lines in vitro, as described (Robinson et al.,
998). RhEBV stocks typically contained 3.5–4.5 trans-
orming units50 per milliliter as determined by end-point
dilution in rhesus peripheral blood mononuclear cells
(PBMC). Rhesus MAbs were derived by the transforma-
tion of B cells from cryopreserved PBMC obtained from
four rhesus macaques 12–13 months following infection
b
swith SIV/17E-CL. RhEBV inoculated PBMC cultures were
plated in multiple 96-well culture plates containing irra-
diated, mature human macrophages as feeder cells as
we have previously described (Robinson et al., 1998).
Enzyme immunoassay for antibody screening
Supernatant fluids from transformed B-cell cultures
were screened for antibodies binding to viral envelope
glycoproteins from SIV/17E-CL, using a “reverse capture”
sandwich immunoassay, according to our published
method (Robinson et al., 1998). Briefly, rhesus MAbs in
culture fluids were first captured in wells of ELISA plates
coated with 1 mg/ml goat anti-human IgG-Fc. Detergent-
olubilized virus containing 10% normal human serum
Irvine Scientific) was incubated in the wells to allow
inding of viral antigens to immobilized antibodies. As-
ay wells in which bound viral envelope glycoproteins
ere captured were detected by the addition of a mixture
f two biotinylated human MAbs, 2.6C and 1.10C, which
ecognize nonoverlapping, well-conserved sites on
p120 of both HIV-2 and SIV. We utilized two noncompet-
ng, biotin-labeled human MAbs to be sure that if a
aptured rhesus MAb competed for the binding site of
ne labeled human MAb, the second labeled human
Ab would still detect bound SIV gp120. The ELISA was
ompleted by the addition of peroxidase-conjugated
treptavidin (Vector Laboratories), and color was devel-
ped by the addition of tetramethylbenzidine (TMB)–
2O2 substrate. Following a 3-min incubation at room
emperature, the color reaction was stopped by the ad-
ition of 1 M phosphoric acid and read as optical density
OD) at 450 nm using an automated plate reader (Dyna-
ech Laboratories, McLean, VA). To control for unaccept-
bly high background signals resulting from binding of
he biotinylated MAbs to the capture antibody, normal
uman serum (10%) was added to the dilution buffer in
oth the virus and the biotin–human MAb steps to satu-
ate all anti-IgG (Fc) binding sites.
hesus MAb purification and biotinylation
Cell lines producing rhesus MAbs were serially sub-
ultured at low cell density and serially subcloned as
escribed previously (Robinson et al., 1998). All rhesus
Ab-producing cell lines were grown in bulk roller bottle
ultures and culture supernatants were harvested
eekly. Rhesus MAbs (and human MAbs) were purified
rom 1–2 liters of culture supernatant by Protein A affinity
hromatography. Purified MAbs were biotinylated with
HS-X-biotin (Calbiochem) as previously described
Robinson et al., 1998). Sodium azide (0.001%) and bovine
erum albumin (1%) were added to the biotinylated anti-
odies as stabilizers and the antibody stocks were
tored at 4°C.
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70 COLE ET AL.Human MAbs to HIV-2 gp120
Human MAbs 1.10C, B23, 1.7A, and 2.6C (Robinson et
al., 1998) were derived by EBV transformation of B cells
from an HIV-2-infected patient from the Ivory Coast ac-
cording to a protocol we established for producing hu-
man MAbs to HIV-1 gp120 (Robinson et al., 1990b). These
human MAbs are broadly reactive with conformation-
dependent epitopes of gp120s from a number of HIV-2
and SIV strains (Robinson et al., 1998). In addition, hu-
an MAbs 1.10C, B23, and 1.7A cross-compete with one
nother and block SIV gp120 binding to CCR5; human
Ab 2.6C recognizes an independent epitope and does
ot block gp120–CCR5 binding (Robinson et al., 1998).
oncanavalin A ELISA
Concanavalin A (Con A) coated in wells of ELISA
lates has been shown to efficiently immobilize HIV-1,
IV-2, and SIV gp120 and thus provide stable, solid-
hase antigen substrates for a variety of ELISAs (Robin-
on et al., 1990b; Clements et al., 1995; Cole et al., 1997b,
998; Robinson et al., 1998). All rhesus MAbs were tested
or binding to Con A immobilized SIV gp120s present in
erum-free culture medium of SIV-infected cells or puri-
ied SIV recombinant envelope proteins as previously
escribed for HIV-1 gp120 (Robinson et al., 1990a) and
odified for SIVmac251 recombinant gp110 (Cole et al.,
997b). The Con A ELISA was also used to determine
ross-competition patterns between MAbs.
ross-competition assays between MAbs and srCD4
Rhesus and human MAbs were tested for binding
ompetition with each other to determine whether they
ecognized overlapping or nonoverlapping sites as pre-
iously described (Robinson et al., 1998). Solubilized
p120 present in detergent-treated SIV/17E-CL serum-
ree culture fluid was immobilized onto Con A (5 mg/well)
oated wells. The plates were washed and blocked with
% whey 1 0.5% Tween 20 in PBS for 30 min at room
emperature. Purified rhesus and human MAbs or dilu-
ion buffer was incubated in the wells for 1 h at room
emperature. Biotinylated rhesus or human MAbs were
hen added to the wells at dilutions that gave less than
aximal binding and incubated for 1 h at room temper-
ture. The ELISA was completed by the addition of per-
xidase-conjugated streptavidin (Vector Laboratories),
nd color was developed by the addition of TMB–H2O2
substrate. The color reaction was stopped by the addi-
tion of 1 M phosphoric acid and read as OD at 450 nm
using an automated plate reader (Dynatech Laborato-
ries). In similar competition assays we examined the
effect of human, recombinant, soluble CD4 (rsCD4) at a
concentration of 10 mg/ml on binding of biotinylated
MAbs to immobilized gp120 and, reciprocally, the effect
of each MAb on rsCD4 binding to gp120. CD4 bindingwas measured using a rabbit antibody to CD4 (both
rsCD4 and rabbit anti-CD4 serum were obtained from the
AIDS Research and Reference Reagent Program, Divi-
sion of AIDS, NIAID, NIH, and were donated by Raymond
Sweet) followed by peroxidase-conjugated anti-rabbit
IgG in a standard ELISA procedure.
Western blot assay
Triton X-100 solubilized lysates from SIV/17E-CL-in-
fected CEMx174 cells were fractionated by SDS–PAGE in
the absence of reducing agents and electrophoretically
transferred to nitrocellulose membranes as previously
described (Robinson et al., 1998). Similar Western blots
ere prepared from purified recombinant gp110
SIVmac251) that had been electrophoresed in the pres-
nce or in the absence of a reducing agent. Reactivity of
he rhesus MAbs with Western blots was detected using
eroxidase-conjugated anti-monkey or anti-human IgG
Sigma). The blots were developed with a metal en-
anced DAB substrate (Pierce Chemical).
8 protease digestion of rgp110
Purified SIVmac251 rgp110 (0.5 mg) was digested with
taphylococcus aureus V8 protease (10 mg) in 1 ml Tris
(pH 8.3) for 4 h at 37°C using the protocol established by
Javaherian et al. (1994). The mixture of digested and
ndigested rgp110 was then fractionated by SDS–PAGE
nd the separated proteins were electrophoretically
ransferred to nitrocellulose membranes. MAbs were
ested for binding to rgp110 or the 45-kDa protease
igestion product.
eptide ELISA
Synthetic overlapping peptides (EVA 774.1–774.49), 20
mino acids in length with 10-amino-acid overlaps cov-
ring the entire sequence of SIVmac251 gp120 (32H
solate), were obtained from the National Institute for
iological Standards and Control Centralised Facility for
IDS Reagents supported by EU Programme EVA (Con-
ract BMH4 97/2515) and the UK Medical Research
ouncil (South Mimms, Potters Bar, Hertsfordshire, UK).
similar set of peptides based on the sequence of
IVmac239 was obtained from the AIDS Research and
eagent Program. Peptides (10 mg/well diluted in 0.05 M
sodium bicarbonate, pH 9.6) were fixed onto the wells of
ELISA plates (Corning or Dynatech Corp.) by incubation
overnight at room temperature. Rhesus MAbs (5 mg/ml)
were tested for binding to solid-phase peptides by
ELISA, and detection of bound MAbs was determined
using peroxidase-conjugated goat anti-monkey or goat
anti-human IgG (Sigma) as previously described (Cole et
al., 2000).
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71NEUTRALIZATION EPITOPES OF SIVVirus neutralization assay
Virus neutralization assays were performed in 96-well
tissue culture plates using an infectivity reduction
method (neutralization index) to determine whether titers
of virus were reduced significantly by a constant con-
centration of MAbs by comparison to titers achieved in
the absence of MAbs (Casals, 1967). Virus stocks were
prepared by inoculation of CEMx174 or D3-R5 cells with
SIV/17E-CL in 25-cm2 culture flasks. Supernatant fluids
ere collected 1 week after inoculation, filtered, ali-
uoted, and stored at 280°C. Serial 10-fold dilutions of
ach virus stock were incubated with a constant con-
entration (10 mg/ml) of each rhesus MAb or medium
alone for 1 h at 37°C. The mixtures were inoculated onto
D3-R5 cells in quadruplicate wells of 96-well plates. Cell
culture medium was changed on day 3 or 4 postinocu-
lation and assayed for the production of viral SIVp24
antigen on day 10 postinoculation using an in-house SIV
p24 antigen-capture assay. Wells were scored as posi-
tive for infection if the OD readings were greater than
0.500 and negative for infection if the OD readings were
less than 0.500 (this cut-off OD value was about threefold
greater than average background OD and discriminated
unequivocally between infected and uninfected cultures).
The end-point infectivity titers were determined using the
method of Karber (1931) and the results are expressed as
a NI or the reduction in log10 TCID50 observed with each
irus–MAb combination compared to the log10 TCID50
achieved with the virus stock titered in the absence of
antibody. NI values of 1.5 or higher indicate neutralization
and are reflective of the mean values obtained for three
independent experiments.
SIV p24 antigen capture assay
A noncommercial SIV p24 (gag) ELISA was performed
as follows: wells of 96-well ELISA plates (Corning) were
coated with 2 mg/ml affinity-purified goat anti-mouse IgG
(Fc) for 1 h at 37°C. Murine MAb 5402 (Clone 10-9C7.4.1,
purchased from Celex Corp., Columbia, MD), which is
reactive with HIV-2/SIV p16, 24, 26, and 56, was incu-
bated at 0.5 mg/ml in the anti-mouse IgG coated wells.
ollowing incubation for 1 h at 37°C, all wells were
ashed with PBS 1 0.1% Triton X-100. Supernatant fluids
rom the transformed B-cell tissue culture plates were
hen incubated with the antibody coated assay plates to
llow capture of any gag proteins present. After incuba-
ion for 90 min at 37°C, the wells were again washed
ith PBS 1 0.1% Triton X-100 and a predetermined opti-
al dilution of biotinylated rhesus IgG (purified by Pro-
ein A chromatography from the serum of an SIV-infected
acaque) diluted in PBS 1 0.5% whey was added to the
ells. Following incubation for 90 min at 37°C, wells
ere washed with PBS 1 0.1% Triton X-100 and incu-
ated with peroxidase-conjugated streptavidin (1:2000 in
BS 1 0.05% Tween 20) for 1 h at room temperature.olor was developed using TMB–H2O2 substrate (Pierce
Chemical Co.), the reaction was stopped at 3 min with 1
M phosphoric acid, and the OD at 450 nm was read
using an automated plate reader (Dynex Corp., McLean,
VA).
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